Guardant Health's Shield blood test for colorectal cancer screening is now covered by TRICARE, providing active duty service ...

Guardant Health, Inc., a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening is now covered for active-duty service members and their families ...

Colonoscopy is the gold standard for detecting colon cancer, but every year about 50 million people in the U.S. who qualify for a colonoscopy don't get it done, according to the American Cancer ...

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, ...

FDA reviewers questioned the potential benefits of Guardant Health's blood-based test for colorectal cancer (CRC) screening in documents released ahead of an advisory committee meeting on Thursday.

FDA panel voted favorably that there is reasonable assurance Shield is safe, effective, and outweigh its risks. The FDA is expected to decide whether to approve Shield later this year. Get ahead of ...